Nuvelo Inc. today announced that it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its lead product candidate, alfimeprase, for the treatment of acute periph
The American Academy of Dermatology (Academy) has issued a statement in response to the U.S. Food and Drug Administration's (FDA) announcement that a black box warning will be added to the labeling and a
After prosecuting the securities litigation claims against Bristol-Myers Squibb Co. (BMS) for over five years, Labaton Sucharow, Lead Counsel representing the class and Lead Plaintiff, the LongView Collective Investment Fund of the Amalgamated Bank, re
Decision Resources, Inc., finds that despite the dominant market position of statins in the treatment of dyslipidemia, only 81% of patients receive a statin as a first-line therapy for the d
A new EU-funded project kicked off this month which aims to bridge the gap between the laboratory and the clinic. The EU Microdose AMS Partnership Programme (EUMAPP) aims to boost Europe's expertise in
Health authorities in the U.S. are recommending that doctors keep a close eye on patients taking Ketek for signs of liver problems and to stop treatment if symptoms develop.The warning follows reports that three patients in North Carolina devel
The recommendation by the National Institute of Clinical Evidence (NICE), that Alzheimer's drugs should be used in a minority of people with the degenerative brain disease, has created both rage and d
An FDA advisory panel has declared that an over-the-counter weight-loss drug appears to be safe and effective for a six month period of use.GlaxoSmithKline's weight-loss drug Alli is said to be a
After the first full week of making information on assured drug price discounts available to beneficiaries, the Centers for Medicare & Medicaid Services' review of the savings offered by drug card sponsors shows that more cards will be offering lowe
Medical students in the U.S. are applauding a study published in the Journal of the American Medical Association (JAMA), which calls for a ban on gifts to doctors from drug companies.The
The agency's tentative approval means that although existing patents and/or exclusivity prevent U.S. marketing of Aspen's product, it meets FDA's quality, safety and efficacy standards for U.S. marketing. This action makes this product available for potential procurement by President Bush's Emergency Plan for AIDS Relief.
Today's action is the first tentative approval of an HIV drug regimen manufactured by a non-U.S.-based generic pharmaceutical company. Once Aspen 's marketing application was complete on January 13, 2005, FDA completed its review within two weeks.
"Today's action honors the commitment of the Department of Health and Human Services and Secretary Thompson to the President's Emergency Plan for AIDS Relief," said Dr. Lester M. Crawford, Acting FDA Commissioner. "The goal of the emergency plan is to make safe, effective and affordable quality drugs available quickly for patients with HIV/AIDS."
"Through an expedited review process, FDA has worked diligently to approve a product with great public health significance. Our contributions to the goals of the emergency plan are an integral part of that effort," added Dr. Crawford.
The Emergency Plan for AIDS Relief, which President Bush first announced in his 2003 State of the Union Address, is currently providing $15 billion to fight the HIV/AIDS pandemic over five years, with a special focus on 15 of the hardest hit countries. It targets three specific areas related to HIV/AIDS:
Prevention of HIV transmission; Treatment of AIDS and associated conditions; Care, including palliative care for HIV infected-individuals, and care for orphans and vulnerable children.The tentatively approved regimen consists of co-packaged lamivudine/zidovudine fixed dose combination tablets and nevirapine tablets. Lamivudine/zidovudine fixed dose combination tablets are a version of the already approved Combivir tablets manufactured by GlaxoSmithKline, and nevirapine tablets are a version of Viramune tablets manufactured by Boehringer-Ingelheim. The new co-packaged product consists of two tablets (lamivudine/zidovudine and nevirapine) each to be taken twice daily, after the initial two-week initiation phase of this nevirapine regimen.
More information on HIV and AIDS is available online at FDA's website.
http://www.fda.gov